Trial Profile
Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Endometrial cancer
- Focus Adverse reactions
- 06 Nov 2020 Status changed from active, no longer recruiting to completed.
- 28 Aug 2019 Planned End Date changed from 28 Feb 2021 to 3 Oct 2020.
- 04 Jun 2019 Interim results of biomarker analysis from patients with pathological response presented at the 55th Annual Meeting of the American Society of Clinical Oncology.